What Drives the Cost of a Healthcare Application

Healthcare applications cost more than comparable consumer software, and the difference is not padding. It comes from three specific areas that ordinary applications do not have, each of which is straightforward to explain and easy to underestimate.

Integration is the largest single factor

A consumer app owns its data. A healthcare app almost never does — the patient record lives in an electronic health record system, results come from a laboratory system, images from an archive, appointments from a scheduling platform.

Connecting to these is where the schedule goes. FHIR has improved matters considerably, but coverage varies by vendor and by installation, and organisations frequently run older HL7 v2 interfaces alongside. The technical work is manageable; the discovery is not. Which fields are actually populated in this instance, as opposed to theoretically supported, is a question only answerable by looking at real data.

The cost driver is therefore the number of systems and how modern their interfaces are, not the number of screens. Two applications with identical user-facing scope can differ by a factor of three on this alone.

Compliance is evidence, and evidence is work

HIPAA and equivalent regimes require controls and the ability to demonstrate them. Access control tied to clinical role, audit trails of who viewed which record, encryption in transit and at rest, defined retention and disposal, and business associate agreements with every processor in the chain.

Most of these are not difficult individually. What costs is producing evidence continuously rather than assembling it before an assessment, and designing so that protected health information does not leak into places nobody classified — logs, analytics events, error reports, support tooling.

Building that in adds meaningfully to the initial cost and is far cheaper than retrofitting. Applications that treat compliance as a pre-launch checklist typically discover architectural problems at the least convenient point.

Clinical safety and validation

If the application influences clinical decisions, it needs clinical involvement in design and testing, which is a cost most software budgets do not include. Clinicians' time is expensive and scarce, and their review is not optional if the product is going to be safe.

Where the product meets the definition of a medical device — which is broader than most teams expect, and can include software that interprets data rather than merely displays it — the regulatory pathway adds substantially more: a quality management system, documented risk management, and a submission process measured in months.

Establishing early whether you are inside or outside that boundary is the single most valuable thing you can do for the budget, because the two answers describe different projects.

Testing costs more because the data is harder

You cannot test with production data. You need synthetic or de-identified data that reproduces the awkward shapes of real records — duplicate patients, merged records, corrected results arriving after the original, values outside expected ranges, and free-text fields containing things nobody anticipated.

Generating that data well is a real piece of work, and skipping it produces the familiar outcome of software that passes QA and fails in a clinic. De-identification itself needs care, since a dataset that permits re-identification is a disclosure.

Accessibility is not optional here

Patient-facing healthcare software is used by people who are unwell, elderly, distracted, in pain, or using assistive technology — disproportionately so compared with a general consumer product.

Building to WCAG 2.2 AA and testing with a screen reader is a genuine line item. It is also frequently a legal requirement, and in this domain the ethical argument is strong enough to stand on its own.

Where costs are commonly underestimated

Interface discovery, because the specification and the instance rarely match. Manual review paths for identity verification and data quality exceptions, which need operational staff as well as software. Ongoing compliance work, which does not stop at launch. And the integration testing window with the client's IT department, whose availability is not within your control.

Operating cost continues after launch

Healthcare applications carry ongoing costs that consumer software does not. Compliance evidence has to keep being produced. Interfaces break when the connected system upgrades, and you do not control that schedule. Access reviews and audit log retention continue indefinitely.

Clinical content — care pathways, drug information, coding sets — needs updating as guidance changes, and stale clinical content is a safety issue rather than a freshness one. If your product depends on it, someone has to own that update cycle.

A reasonable planning assumption is that annual running cost is a substantial fraction of the original build, higher than for comparable non-healthcare software. Budgets that treat launch as the end of spending tend to be the ones where interfaces quietly stop working.

Procurement lengthens the timeline more than engineering does

Selling into healthcare organisations involves information governance review, security assessment, clinical safety review and often a formal procurement process. Each has its own queue, and they frequently run in sequence rather than in parallel.

The engineering consequence is that evidence needs to exist before the review rather than being produced in response to it. Security documentation, data flow diagrams, a data protection impact assessment and a clinical safety case are all artefacts that take time and are best produced alongside the build.

Teams that plan for a launch date without accounting for these are usually the ones whose product is finished for months before anyone can use it.

Where to spend and where not to

Spend on integration discovery early, before committing to a schedule, because it determines everything after it. Spend on compliance architecture, since it is cheap now and expensive later. Spend on realistic test data.

Save by narrowing initial scope to one clinical workflow done properly rather than several done partially, and by deferring anything that pushes you across the medical device boundary until you have decided deliberately to cross it.